Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
Related to this article
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.
Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy
Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.
Advertisement
Advertisement
Trending on OncLive
1
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
2
Northwestern Medicine Study Finds Lung Transplant Dramatically Improves Survival for Patients With Terminal Lung Cancer
3
STRIDE Plus TACE With/Without Lenvatinib Improves Responses in Embolization-Eligible HCC
4
Dr Spencer on the Potential Role for In Vivo CAR T-Cell Therapy in Myeloma
5